Events & Implementation Activities
Where personalised medicine moves from discussion to delivery.
IPM Alliance convenes political, scientific, clinical, patient, industry and health-system stakeholders to address the practical barriers that prevent personalised medicine from reaching patients.
Across political sessions, implementation labs, congress-side meetings, expert roundtables and business-facing innovation meetings, our events are designed to produce more than discussion. They create policy signals, implementation briefs, pathway prototypes, stakeholder takeaways, readiness maps and follow-up workstreams.
Events
Featured upcoming activities
Explore upcoming IPM Alliance events and implementation activities across global policy, regional engagement, scientific congresses and business-facing innovation settings.
Bringing Innovation into Healthcare Systems: From Promising Science and AI to Routine Patient Benefit
A high-level conference during United Nations General Assembly High-Level Week examining how AI, personalised medicine and other health innovations can move beyond research projects and pilots to become safe, scalable, sustainable and equitable components of routine care. The meeting will bring together governments, healthcare systems, patients, clinicians, regulators, payers, investors, innovators, industry, technology leaders and international organisations to examine the full innovation-to-care pathway and identify the frameworks, governance and system capacity needed to translate promising science into sustainable patient benefit.
Expected output:
The New York Framework for Innovation-to-Care The meeting will conclude with a practical framework comprising system-readiness tests and international principles for selecting, adopting, scaling and sustaining health innovation. The framework will be built around six practical readiness questions: Need – Does the innovation address a clearly defined patient or health-system priority? Evidence and Value – Is there sufficient evidence of benefit, usability and system value? Integration – Can it fit clinical workflows, workforce and data systems? Adoption and Financing – Is there a credible route through regulation, HTA, reimbursement and procurement? Scale and Sustainability – Who will own, finance, operate and maintain it over time? Equity and Trust – Can it improve access while maintaining appropriate governance and patient confidence?
China Precision Oncology Sessions
A China-focused precision oncology implementation event examining how clinical trials and AI-enabled innovation can translate into trusted, timely and equitable patient access. The event will connect global evidence generation, local implementation, trial matching, diagnostics, patient navigation, real-world evidence and responsible AI governance.
Expected output:
The event is designed to produce China-focused implementation outputs, including: - practical principles for aligning clinical trial design with local access needs; - recommendations for integrating biomarker testing, imaging, digital pathology and trial matching into routine care; - approaches for using real-world evidence to support regulatory, HTA and reimbursement decisions; - a patient-centred framework for responsible AI leapfrogging in precision oncology; - priority AI use cases for near-term access improvement; - China-focused collaboration opportunities around hospital research networks, registries, digital pathology validation, trial matching, trusted data governance and real-world evidence.
ASCO Oncology Pillar Launch
A high-level ASCO-side launch session introducing the Oncology Pillar of the International Alliance for Personalised Medicine. The session will bring together oncology leaders, clinical innovators, policymakers, payers, HTA and regulatory experts, diagnostics and data partners, patient voices and industry leaders to discuss how precision oncology can move from breakthrough science to routine, equitable real-world delivery.
Expected output:
Oncology Pillar launch, Leadership Circle, founding stakeholder alignment and 12-month roadmap.
From Capital to Care
A J.P. Morgan Week side event focused on how personalised medicine can move from scientific promise and investment potential to routine patient benefit. The forum will examine the policy, investment, regulatory, reimbursement, data, AI and health-system conditions needed to make personalised medicine investable, scalable, reimbursable and accessible.
Expected output:
The event is designed to produce a Policy-Investor Compact for Personalised Medicine, setting out practical commitments across: - trusted data infrastructure for personalised medicine; - credible evaluation standards for AI and digital health tools; - earlier molecular profiling and matched therapies; - alignment of regulatory, HTA and reimbursement pathways; - investment in diagnostic readiness and workforce capacity; - business models that balance innovation, sustainability and patient access; - measurable patient benefit as the core test of value.
Irish Presidency Policy Conference
A Dublin policy conference during the Irish Presidency focused on how Europe can move personalised medicine from innovation to routine patient benefit. The event will examine the practical barriers between scientific progress and access, including innovation funding, reimbursement, diagnostic readiness, clinical trials, data infrastructure and health-system implementation.
Expected output:
A Dublin Personalised Medicine Access Brief setting out practical policy priorities from the conference, including: - how Europe can strengthen the innovation-to-access pathway; - whether a European Health Innovation Fund or similar mechanism could support earlier and fairer adoption; what diagnostic infrastructure is needed for precision oncology; - how clinical trial evidence, regulation, HTA, reimbursement and diagnostic readiness can be better aligned; - what follow-up commitments should be taken forward after the Irish Presidency conference.
MFN, Trade & Tariffs: Personalised Medicine
An evidence-led international conference examining how MFN drug-pricing policies, tariffs, localisation and trade realignment could affect personalised medicine, including innovation, launch sequencing, diagnostics, clinical research, manufacturing, supply chains and equitable patient access.
Expected output:
The New York Principles on MFN, Trade and Personalised Medicine, a practical framework outlining policy safeguards and monitoring priorities for innovation, diagnostics, clinical research and equitable access. The proposed principles will address patient-access testing, international spillovers, protection of diagnostics and clinical research, future innovation, resilient supply chains, transparent monitoring, international dialogue and periodic policy review based on real-world evidence.
ESMO 2026 Personalised Oncology Session
A full-day ESMO-side session in Madrid focused on how personalised oncology can move from molecular insight to measurable patient access. The meeting will examine whether health systems can identify the right patient, deliver the right test, interpret the result, act on eligibility and measure whether access has improved.
Expected output:
The session is designed to produce practical post-ESMO outputs, including: - ESMO Personalised Oncology Access Statement; - five to seven implementation priorities across diagnostics, treatment access, reimbursement, data, prevention, supportive care and equity; - eligibility-to-access pathway map; - post-ESMO policy communiqué; - stakeholder consultation route involving clinicians, patients, policymakers, payers, diagnostics leaders, researchers and innovation partners; - follow-up route with SYNTHIA, BRECISE, SPARC, ON-COME and iBeChange.